Blood Eosinophils and Pulmonary Rehabilitation in COPD.

Szczegóły
Abstrakt

Tytuł:: Blood Eosinophils and Pulmonary Rehabilitation in COPD.
Autorzy:: Aljazeeri J; University of Pittsburgh Medical Center, Pennsylvania, USA.; Drexel University College of Medicine, Pennsylvania, USA.
Sakkat A; McMaster University, Department of Medicine, Division of Respirology, Hamilton, Canada.
Makhdami N; Firestone Institute for Respiratory Health, St Joseph Healthcare, Hamilton, Canada.
Almusally R; Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Morfaw F; McMaster Univerisity, Department of Health Research Methods, Evidence and Impact, Hamilton, Canada.
McIvor A; McMaster University, Department of Medicine, Division of Respirology, Hamilton, Canada.; Firestone Institute for Respiratory Health, St Joseph Healthcare, Hamilton, Canada.
Źródło:: Canadian respiratory journal [Can Respir J] 2021 Nov 05; Vol. 2021, pp. 7449527. Date of Electronic Publication: 2021 Nov 05 (Print Publication: 2021).
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: <2015- > : Cairo : Hindawi Publishing Corporation
Original Publication: Oakville, Ont. : Pulsus Group Inc., 1994-
MeSH Terms:: Eosinophils*
Pulmonary Disease, Chronic Obstructive*
Humans ; Lung ; Retrospective Studies ; Severity of Illness Index ; Walk Test
References:: Cochrane Database Syst Rev. 2016 Dec 08;12:CD005305. (PMID: 27930803)
Respir Med. 2009 Mar;103(3):373-8. (PMID: 19013781)
Ann Allergy Asthma Immunol. 2017 Jul;119(1):16-20. (PMID: 28668237)
N Engl J Med. 2004 Mar 4;350(10):1005-12. (PMID: 14999112)
Eur Respir J. 2014 Dec;44(6):1447-78. (PMID: 25359356)
Lancet Respir Med. 2018 Feb;6(2):117-126. (PMID: 29331313)
Eur Respir J. 2014 Dec;44(6):1428-46. (PMID: 25359355)
Int J Chron Obstruct Pulmon Dis. 2018 Oct 08;13:3131-3139. (PMID: 30349221)
Lancet Respir Med. 2015 Jun;3(6):435-42. (PMID: 25878028)
Eur Respir J. 2014 Dec;44(6):1697-700. (PMID: 25323230)
Am J Respir Crit Care Med. 2018 Nov 15;198(10):1268-1278. (PMID: 29763572)
J Allergy Clin Immunol. 2018 Jun;141(6):2037-2047.e10. (PMID: 29709670)
Respir Med. 2009 Jul;103(7):1070-5. (PMID: 19217765)
Am J Respir Crit Care Med. 2012 Jul 1;186(1):48-55. (PMID: 22447964)
N Engl J Med. 2018 May 03;378(18):1671-1680. (PMID: 29668352)
COPD. 2004 Apr;1(1):105-41; discussion 103-4. (PMID: 16997745)
Chest. 2002 Apr;121(4):1092-8. (PMID: 11948037)
Cochrane Database Syst Rev. 2015 Feb 23;(2):CD003793. (PMID: 25705944)
Chest. 2017 Feb;151(2):366-373. (PMID: 27746201)
Am J Respir Crit Care Med. 2013 Oct 15;188(8):e13-64. (PMID: 24127811)
Am J Respir Crit Care Med. 1999 Jan;159(1):321-40. (PMID: 9872857)
Am J Respir Crit Care Med. 2016 May 1;193(9):965-74. (PMID: 26641631)
Am J Respir Crit Care Med. 2015 Aug 15;192(4):523-5. (PMID: 26051430)
Respir Res. 2012 Sep 25;13:85. (PMID: 23006638)
N Engl J Med. 2017 Oct 26;377(17):1613-1629. (PMID: 28893134)
Nat Rev Immunol. 2008 Mar;8(3):183-92. (PMID: 18274560)
Am J Respir Crit Care Med. 2008 Sep 1;178(5):491-9. (PMID: 18535255)
Am J Med. 2006 Oct;119(10 Suppl 1):12-20. (PMID: 16996895)
Thorax. 2013 Sep;68 Suppl 2:ii1-30. (PMID: 23880483)
Entry Date(s):: Date Created: 20211115 Date Completed: 20220117 Latest Revision: 20240404
Update Code:: 20240404
PubMed Central ID:: PMC8589509
DOI:: 10.1155/2021/7449527
PMID:: 34777651
: Czasopismo naukowe

Full Text Finder

Background: Blood eosinophils predict the response to therapy, risk of exacerbation, and readmission in COPD. This study investigates whether blood eosinophils predict pulmonary rehabilitation (PR) outcomes in COPD.
Methods: We categorized patients into eosinophilic (blood eosinophils ≥300 cells/ml) or noneosinophilic (<300 cells/ml). In a retrospective design, we compared changes within and between the two groups on BODE index, 6-minute walk test (6MWT), FEV1, and mMRC dyspnea scale.
Results: Of 206 patients enrolled, 176 were included for analysis; 90 were eosinophilic. BODE index improved in both groups: (MD -1.25; 95% CI (-0.45, -4.25), P ≤ 0.001) in the eosinophilic and (MD -1.33; 95% CI (-1.72, -0.94), P ≤ 0.001) in the noneosinophilic, but a higher BODE index remained in the eosinophilic (4.98); adjusted mean change ( β ): 0.7 (95% CI (0.15, 1.26), P =0.01). 6MWT improved by 29.3 m in the eosinophilic (95% CI (14.2, 44.4), P ≤ 0.001) vs. 115.1 m in the noneosinophilic (95% CI (-30.4, 260.6), P =0.12). FEV1 did not change in the eosinophilic (MD -0.6; 95% CI (-2.64, 1.48), P =0.58), but improved by 2.5% in the noneosinophilic (MD 2.5; 95% CI (0.77, 4.17), P =0.005). There were no significant between-group differences in 6MWT and FEV1; adjusted mean changes ( β ) were -9.69 m (95% CI (-39.51, 20.14), P =0.52) and -2.31% (95% CI (-5.69, 1.08), P =0.18), respectively. There were no significant within- or between-group changes in the mMRC scale.
Conclusion: Although PR improves the BODE index in both eosinophilic and noneosinophilic COPD, a higher eosinophil count (≥300 cells/ml) is associated with a higher (worse) BODE index. Blood eosinophils may predict PR outcomes.
Competing Interests: The authors declare that they have no conflicts of interest.
(Copyright © 2021 Jafar Aljazeeri et al.)

Informacja